Clopidogrel and genetic testing: Is it necessary for everyone?

Cardiology in Review

Volumn 20, Issue 2, 2012, Pages 96-100

  Goswami, Sweta ^a,b   Cheng Lai, Angela ^a,b   Nawarskas, James ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

clopidogrel; CYP2C19; genetic polymorphisms; genetic variants

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; 2 OXOCLOPIDOGREL; ARYLDIALKYLPHOSPHATASE 1; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; R 130964; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERICUM PERFORATUM; LOSS OF FUNCTION MUTATION; META ANALYSIS (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PATIENT COMPLIANCE; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ARTERIOSCLEROSIS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; GENETIC TESTING; GENOTYPE; HUMANS; META-ANALYSIS AS TOPIC; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RECURRENCE; TICLOPIDINE; UNNECESSARY PROCEDURES;

EID: 84857356069     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182455744     Document Type: Article

References (40)

1. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
2. Mehta SR, Yusuf S, Peters RJ, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527-533. (Pubitemid 32772726)
3. Yusuf S, Zhao F, Mehta SR, et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
4. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation. 2011;123:e18-e209.
5. Breslow JM. FDA Adds Black-Box Warning to Plavix. PBS website http:// www.pbs.org/newshour/rundown/2010/03/fda-adds-toughest-warning-to- lavix. html. March 12, 2010. Accessed November 16, 2011.
6. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009;360:411-413.
7. Par G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704-1714.
8. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet. 2009;373:309-317.
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
10. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
11. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19. 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.
12. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Food and Drug Administration Web site. http://www.fda.gov/drugs/drugsafety/Postmarket- DrugSafetyInformationforPatients andProviders/ucm203888.htm. March 25, 2010. Accessed November 30, 2011.
13. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011.
14. Johnson JA, Cavallari LH, Beitelshees AL, et al. Pharmacogenomics: Application to the management of cardiovascular disease. Clin Pharmacol Ther. 2011;90:519-531.
15. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: Towards personalized therapy? Nat Rev Cardiol. 2011;8:560-571.
16. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation. 2010;121:481-483.
17. Smock KJ, Saunders PJ, Rodgers JM, Johari V. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol. 2011;86:1032-1034.
18. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis. 2011;32:459-466.
19. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA. 2010;304:1821-1830.
20. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. (Pubitemid 44497506)
21. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916-922.
22. Bhatt DL. TCT 2009; September 21-25, 2009; San Francisco, CA.
23. Kremen R. CHARISMA Genomics Substudy links loss-of-function allele and bleeding. SearchEngine Watch Web site. Theheart.org. http://www.theheart. org/article/1008623.do. September 28, 2009. Accessed November 19, 2011.
24. Wallentin L, James S, Storey RF, et al.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet. 2010;376:1320-1328.
25. Simon T, Verstuyft C, Mary-Krause M, et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
26. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19. 2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
27. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
28. Price M. ACC 2011; April 5, 2011; New Orleans, LA.
29. Price MJ, Berger PB, Teirstein PS, et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA. 2011;305:1097-1105.
30. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221-2228.
31. GIANT ongoing trial-US National Library of Medicine. ClinicalTrials. gov [online]. http://clinicaltrial.gov/ct2/show/NCT01134380 (2010). Accessed November 10, 2011.
32. GeCCo ongoing trial-US National Library of Medicine. ClinicalTrials. gov [online]. http://clinicaltrial.gov/ct2/show/NCT00995514 (2009). Accessed November 10, 2011.
33. RAPID-STEMI ongoing trial-US National Library of Medicine. Clinical- Trials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01452139 (2011). Accessed January 3, 2012.
34. Par G, Eikelboom JW, Sibbing D, et al. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2011;4:514-21; discussion 521.
35. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet. 2010;376:1312-1319.
36. Bouman HJ, Schanig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-116.
37. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32:1605-1613.
38. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non- ST-Elevation Myocardial Infarction (Updating the 2007 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57:1920-1959.
39. Sibbing D, Bernlochner I, Kastrati A, et al. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv. 2011;4:505-13; discussion 513.
40. Qureshi Z, Hobson AR. Clopidogrel Resistance: Where are we now? Cardiovas Ther. August 3, 2011. DOI: 10.1111/j/1755-5922.2011.00296.x.